Hormone Resistant Prostate Cancer Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Radiotherapy in Oligometastatic Prostate Cancer
Prostate cancer ranges from localized, low risk to metastatic, morbid disease. While radiotherapy is commonly incorporated in the treatment of early disease or for palliation of symptomatic lesions, its role in extending survival in metastatic disease is less well-established. Here, we review the available evidence surrounding localized radiotherapy in the presence of oligometastatic disease and metastasis-directed therapy in both hormone-sensitive and hormone-resistant prostate cancer. We further outline potential future incorporation of radiotherapy as an immune-sensitizing therapy and the importance of highly sensitive ...
Source: International Journal of Radiation Oncology * Biology * Physics - July 22, 2022 Category: Radiology Authors: Siven Chinniah, Bradley Stish, Brian A. Costello, Lance Pagliaro, Daniel Childs, Fernando Quevedo, Fabrice Lucien, Alan Bryce, Sean S. Park, Jacob J. Orme Tags: Review Article Source Type: research

Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancer-Prevalence and Current Clinical Practice
CONCLUSIONS: In this study, nearly a third of patients on ARTT for CRPC were found to have OPD. OPD patients had a better PSA response on ART and a longer duration on ARTT before developing OPD as compared to those developing polyprogressive disease (Poly-PD). The majority of patients (70%) with OPD had lesions suitable for SBRT treatment. Prospective randomized control trials are needed to establish if there is a survival benefit of SBRT in oligoprogressive prostate cancer and to determine predictive indicators.PMID:35656509 | PMC:PMC9152030 | DOI:10.3389/fonc.2022.862995 (Source: Cancer Control)
Source: Cancer Control - June 3, 2022 Category: Cancer & Oncology Authors: Priyanka H Patel Nina Tunariu Daniel S Levine Johann S de Bono Rosalind A Eeles Vincent Khoo Julia Murray Christopher C Parker Angela Pathmanathan Alison Reid Nicholas van As Alison C Tree Source Type: research

Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancer —Prevalence and Current Clinical Practice
ConclusionsIn this study, nearly a third of patients on ARTT for CRPC were found to have OPD. OPD patients had a better PSA response on ART and a longer duration on ARTT before developing OPD as compared to those developing polyprogressive disease (Poly-PD). The majority of patients (70%) with OPD had lesions suitable for SBRT treatment. Prospective randomized control trials are needed to establish if there is a survival benefit of SBRT in oligoprogressive prostate cancer and to determine predictive indicators. (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - May 17, 2022 Category: Cancer & Oncology Source Type: research

Cancers, Vol. 14, Pages 1970: A Mutated Prostatic Acid Phosphatase (PAP) Peptide-Based Vaccine Induces PAP-Specific CD8+ T Cells with Ex Vivo Cytotoxic Capacities in HHDII/DR1 Transgenic Mice
Conclusions: The periphery of patients with PCa exhibits immune responsiveness to the MutPAP42mer peptide and immunization of mice induces/expands T cell-driven, wild-type PAP immunity, and therefore, has the potential to drive protective anti-tumor immunity in patients with PCa. (Source: Cancers)
Source: Cancers - April 13, 2022 Category: Cancer & Oncology Authors: Pauline Le Vu Jayakumar Vadakekolathu Sarra Idri Holly Nicholls Manon Cavaignac Stephen Reeder Masood A. Khan Dennis Christensen Alan Graham Pockley St éphanie E. McArdle Tags: Article Source Type: research

Lovastatin enhances chemosensitivity of paclitaxel-resistant prostate cancer cells through inhibition of CYP2C8
In this study, we used prostate cancer cell line PC3 and its paclitaxel-resistant counterpart PC3-TxR as the cell model. Alamar Blue cell viability assay showed that LV and paclitaxel each conferred concentration-dependent inhibition of PC3-TxR cells. When paclitaxel was combined with LV, the proliferation of PC3-TxR cells was synergistically inhibited, as demonstrated by combination index <1. Moreover, colony formation decreased while apoptosis increased in paclitaxel plus LV group compared with paclitaxel alone group. Quantitative RT-PCR showed that the combination of paclitaxel and LV could significantly reduce the e...
Source: Biochemical and Biophysical Research communications - December 13, 2021 Category: Biochemistry Authors: Ying Li Sisi Chen Jianyu Zhu Chanjuan Zheng Muyao Wu Lian Xue Guangchun He Shujun Fu Xiyun Deng Source Type: research

Cancers, Vol. 13, Pages 3904: PSMA Theranostics: Science and Practice
Mike Sathekge Prostate cancer (PCa) causes significant morbidity and mortality in men globally. While localized PCa may be managed with curative intent by surgery and/or radiation therapy, the management of advanced hormone resistant metastatic disease (mCRPC) is more challenging. Theranostics is a principle based on the ability to use an organ specific ligand and label it to both a diagnostic and a therapeutic agent. The overexpression of prostate specific membrane antigen (PSMA) on prostate cancer cells creates a unique opportunity for development of targeted radionuclide therapy. The use of both beta and alpha emitt...
Source: Cancers - August 2, 2021 Category: Cancer & Oncology Authors: Kgomotso Mokoala Ismaheel Lawal Thabo Lengana Mankgopo Kgatle Frederik Giesel Mariza Vorster Mike Sathekge Tags: Review Source Type: research

68Ga-PSMA-11 PET imaging in patients with ongoing androgen deprivation therapy for advanced prostate cancer
ConclusionsIn this study, we observed an overall very high detection rate of 94% using PSMA PET imaging in patients with advanced PCa and ongoing ADT. Even in a majority of patients with very low PSA values < 1 ng/ml PSMA-positive lesions were found. (Source: Annals of Nuclear Medicine)
Source: Annals of Nuclear Medicine - June 29, 2021 Category: Nuclear Medicine Source Type: research

Changes in phospholipid metabolism in exosomes of hormone-sensitive and hormone-resistant prostate cancer cells
Conclusions: This study demonstrates that phosphatidylcholine and its harmful product lysophosphatidylcholine may play important roles in hormone-sensitive prostate cancer. Phospholipid exosome metabolism was changed in hormone-sensitive and hormone-resistant prostate cancer cells. The LPC, lipid pathway of autophagy and ferroptosis may act as therapeutic targets. The possibility of purifying prostate cancer cell exosomes using modified PEG precipitation is suitable for cancer screening. (Source: Journal of Cancer)
Source: Journal of Cancer - April 19, 2021 Category: Cancer & Oncology Authors: Xianlin Yi, You Li, XiaoGang Hu, FuBing Wang, Tiangang Liu Tags: Research Paper Source Type: research

Beyond CAR T Cells: Other Cell-Based Immunotherapeutic Strategies Against Cancer
Conclusions: CAR T cell therapies have demonstrated the clinical benefits of harnessing our body's own defenses to combat tumor cells. Similar research is being conducted on lesser known modifications and gene-modified immune cells, which we highlight in this review. Introduction Chimeric antigen receptors and engineered T cell receptors (based on previously identified high affinity T cell receptors) function by redirecting T cells to a predefined tumor-specific (or tumor-associated) target. Most of these modifications use retroviral or lentiviral vectors to integrate the construct, and most of the receptors ...
Source: Frontiers in Oncology - April 9, 2019 Category: Cancer & Oncology Source Type: research

The Functional Role of Prostate Cancer Metastasis-related Micro-RNAs
The mortality of patients with hormone-resistant prostate cancer can be ascribed to a large degree to metastasis to distant organs, predominantly to the bones. In this review, we discuss the contribution of micro-RNAs (miRs) to the metastatic process of prostate cancer. The criteria for selection of miRs for this review were the availability of preclinical in vivo metastasis-related data in conjunction with prognostic clinical data. Depending on their function in the metastatic process, the corresponding miRs are up- or down-regulated in prostate cancer tissues when compared to matching normal tissues. Up-regulated miRs pr...
Source: Cancer Genomics and Proteomics - December 26, 2018 Category: Cancer & Oncology Authors: WEIDLE, U. H., EPP, A., BIRZELE, F., BRINKMANN, U. Tags: Article Source Type: research

The Combination of Omega-3 Stearidonic Acid and Docetaxel Enhances Cell Death over Docetaxel Alone in Human Prostate Cancer Cells
Background: Docetaxel (DOC), or Taxotere, is an anthracycline antibiotic used to treat multiple types of cancer. It is a first-line chemotherapy treatment for patients with metastasized, hormone-resistant prostate cancer (PCa) or for patients with high-risk, localized PCa that could benefit from early chemotherapy treatment. Previously, we showed that stearidonic acid (SDA), an omega-3 fatty acid, enhances the cytotoxicity of doxorubicin (DOX) in human PCa cells. This observation suggests that PCa therapies using SDA and chemotherapeutic drugs in combination offer attractive possibilities for developing treatments that ame...
Source: Journal of Cancer - December 14, 2018 Category: Cancer & Oncology Authors: Mahmoud Mansour, Sabrina van Ginkel, John C. Dennis, Brandon Mason, Isra Elhussin, Kodye Abbott, Satyanarayana R Pondugula, Temesgen Samuel, Edward Morrison Tags: Research Paper Source Type: research

Docetaxel-induced radiation recall dermatitis with atypical features: A case report
Conclusions: This case report draws attention to the development of atypical RRD after administration of docetaxel and advises careful follow-up even if RRD does not appear after the first docetaxel administration. (Source: Medicine)
Source: Medicine - September 1, 2018 Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research

PET/CT evaluation of prostate cancer patients with Al18F-PSMA-HBED-CC: a head-to-head comparison with 68Ga-PSMA-HBED-CC.
1499Objectives: PSMA-targeting PET tracers have become available for imaging due to the over expression of PSMA in prostate cancer (PC) lesions. 68Ga-PSMA-HBED-CC (68Ga-PSMA-611, ABX) PET/CT represents a clinically relevant and commonly used technique for the evaluation of these patients. 68Ga labeled compounds are produced with generators providing limited activity per synthesis (1 to 4 patients per batch). 18F-labelled tracers, like Al18F-PSMA-HBED-CC (Al18F-PSMA-611, ABX), can be produced in larger scale with a lower positron energy that potentially offers higher image quality as well as the possibility to acquire late ...
Source: Journal of Nuclear Medicine - May 23, 2018 Category: Nuclear Medicine Authors: Alonso, O., dos Santos, G., Giglio, J., Savio, E., Engler, H. Tags: Prostate Posters Source Type: research